- Annual General and Special Meeting of Shareholders scheduled
for May 31, 2019 at 11 a.m. (Toronto
time).
- Proxy voting deadline is May 29,
2019 at 11 a.m. (Toronto time).
- Board of Directors recommends that Shareholders vote FOR all
resolutions.
TORONTO, May 10, 2019 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQB:
KHRNF), (Frankfurt:
A2JMZC), a medical cannabis company with core operations in
Latin America, today announced it has commenced the mailing of
the management information circular and other related materials
(collectively, the "Meeting Materials") to Khiron's
shareholders ("Shareholders") in connection with the annual
general and special meeting of Shareholders (the "Meeting").
The Meeting Materials have also been filed with regulators and
electronic copies are available on SEDAR under its profile at
www.sedar.com.
The Meeting is scheduled to be held on Friday, May 31, 2019 at 11:00 a.m. (Toronto time) at 1600-100 King St. W.,
Toronto, ON M5X 1G5.
Cast Your Vote in Support
Shareholders are encouraged to read the Meeting Materials in
detail and cast their vote in favour of all resolutions prior to
the proxy voting cut-off on May 29,
2019 at 11 a.m. (Toronto time). Voting is easy. Shareholders
may vote online, by telephone or other methods described in the
form of proxy or voting instruction form that shareholders will
receive in the mail.
The Board of Directors of Khiron UNANIMOUSLY
recommends that Shareholders Vote FOR all proposed
resolutions.
Shareholder Questions
Shareholders who have questions or require assistance with
voting may contact Khiron's Proxy Solicitation Agent:
Laurel Hill Advisory Group
North America toll-free:
1-877-452-7184
International: 416-304-0211
Email: assistance@laurelhill.com
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant
integrated cannabis company in Latin
America. Khiron has core operations in Latin America and is fully licensed in the
country for the cultivation, production, domestic distribution, and
international export of both THC (tetrahydrocannabinol) and CBD
(cannabidiol) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
the first Colombian based medical cannabis company to trade on any
exchange globally.
With a focused regional strategy and patient oriented approach,
the Company combines global scientific expertise, agricultural
advantages, branded product market entrance experience and
education to drive prescription and brand loyalty to address
priority medical conditions such as chronic pain, epilepsy,
depression and anxiety in the Latin American market of over 620
million people. Khiron is led by Co-founder and Chief Executive
Officer, Alvaro Torres, together
with an experienced executive team, and a knowledgeable Board of
Directors that includes former President of Mexico, Vicente
Fox.
Further information on Khiron Life Sciences can be found
at www.khiron.ca.
To be added to the distribution list, please email
khiron@kcsa.com with "Khiron" in the subject line.
Cautionary Notes
Forward-Looking Statements
This news release may contain "forward-looking information" and
"forward-looking statements" within the meaning of applicable
Canadian securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Forward-looking are based upon a number of assumptions
that, while considered reasonable by management, are inherently
subject to business, market and economic risks, uncertainties and
contingencies that may cause actual results, performance or
achievements to be materially different from those expressed or
implied by forward-looking statements. Except as required by law,
the Company disclaims any obligation to update or revise any
forward-looking statements. Readers are cautioned not to put undue
reliance on these forward-looking statements.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
SOURCE Khiron Life Sciences Corp.